652 related articles for article (PubMed ID: 33143506)
1. Emerging systemic therapies for atopic dermatitis: oral small molecules and targeted topical agents.
Nusbaum KB; Nguyen CM; Fleischer AB
J Dermatolog Treat; 2022 May; 33(3):1274-1278. PubMed ID: 33143506
[TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial.
Reich K; Teixeira HD; de Bruin-Weller M; Bieber T; Soong W; Kabashima K; Werfel T; Zeng J; Huang X; Hu X; Hendrickson BA; Ladizinski B; Chu AD; Silverberg JI
Lancet; 2021 Jun; 397(10290):2169-2181. PubMed ID: 34023009
[TBL] [Abstract][Full Text] [Related]
3. Evaluating topical JAK inhibitors as a treatment option for atopic dermatitis.
Fardos MI; Singh R; Perche PO; Kelly KA; Feldman SR
Expert Rev Clin Immunol; 2022 Mar; 18(3):221-231. PubMed ID: 34637367
[TBL] [Abstract][Full Text] [Related]
4. New molecules for atopic dermatitis treatment beyond biological therapy.
Freitas E; Torres T
Curr Opin Allergy Clin Immunol; 2023 Jun; 23(3):210-215. PubMed ID: 37185825
[TBL] [Abstract][Full Text] [Related]
5. Topical tacrolimus for atopic dermatitis.
Cury Martins J; Martins C; Aoki V; Gois AF; Ishii HA; da Silva EM
Cochrane Database Syst Rev; 2015 Jul; 2015(7):CD009864. PubMed ID: 26132597
[TBL] [Abstract][Full Text] [Related]
6. Delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with moderate to severe atopic dermatitis: A phase 3, randomized, double-blind, vehicle-controlled study and an open-label, long-term extension study.
Nakagawa H; Nemoto O; Igarashi A; Saeki H; Kaino H; Nagata T
J Am Acad Dermatol; 2020 Apr; 82(4):823-831. PubMed ID: 32029304
[TBL] [Abstract][Full Text] [Related]
7. Treatments for Childhood Atopic Dermatitis: an Update on Emerging Therapies.
Chu CY
Clin Rev Allergy Immunol; 2021 Oct; 61(2):114-127. PubMed ID: 32607924
[TBL] [Abstract][Full Text] [Related]
8. Systematic review and meta-analysis of randomized clinical trials (RCTs) comparing topical calcineurin inhibitors with topical corticosteroids for atopic dermatitis: A 15-year experience.
Broeders JA; Ahmed Ali U; Fischer G
J Am Acad Dermatol; 2016 Aug; 75(2):410-419.e3. PubMed ID: 27177441
[TBL] [Abstract][Full Text] [Related]
9. Review of Atopic Dermatitis and Topical Therapies.
Mayba JN; Gooderham MJ
J Cutan Med Surg; 2017; 21(3):227-236. PubMed ID: 28300440
[TBL] [Abstract][Full Text] [Related]
10. Guidelines of care for the management of atopic dermatitis in adults with phototherapy and systemic therapies.
Davis DMR; Drucker AM; Alikhan A; Bercovitch L; Cohen DE; Darr JM; Eichenfield LF; Frazer-Green L; Paller AS; Schwarzenberger K; Silverberg JI; Singh AM; Wu PA; Sidbury R
J Am Acad Dermatol; 2024 Feb; 90(2):e43-e56. PubMed ID: 37943240
[TBL] [Abstract][Full Text] [Related]
11. JAK inhibitors in the treatment of atopic dermatitis.
Chovatiya R; Paller AS
J Allergy Clin Immunol; 2021 Oct; 148(4):927-940. PubMed ID: 34437922
[TBL] [Abstract][Full Text] [Related]
12. Innovation in the treatment of atopic dermatitis: Emerging topical and oral Janus kinase inhibitors.
Nakashima C; Yanagihara S; Otsuka A
Allergol Int; 2022 Jan; 71(1):40-46. PubMed ID: 34815171
[TBL] [Abstract][Full Text] [Related]
13. What's New in Topicals for Atopic Dermatitis?
Kleinman E; Laborada J; Metterle L; Eichenfield LF
Am J Clin Dermatol; 2022 Sep; 23(5):595-603. PubMed ID: 36048410
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and Safety of Oral Janus Kinase 1 Inhibitor Abrocitinib for Patients With Atopic Dermatitis: A Phase 2 Randomized Clinical Trial.
Gooderham MJ; Forman SB; Bissonnette R; Beebe JS; Zhang W; Banfield C; Zhu L; Papacharalambous J; Vincent MS; Peeva E
JAMA Dermatol; 2019 Dec; 155(12):1371-1379. PubMed ID: 31577341
[TBL] [Abstract][Full Text] [Related]
15. Safety of topical medications in the management of paediatric atopic dermatitis: An updated systematic review.
Zhao S; Hwang A; Miller C; Lio P
Br J Clin Pharmacol; 2023 Jul; 89(7):2039-2065. PubMed ID: 37075252
[TBL] [Abstract][Full Text] [Related]
16. Innovation in Atopic Dermatitis: From Pathogenesis to Treatment.
Munera-Campos M; Carrascosa JM
Actas Dermosifiliogr (Engl Ed); 2020 Apr; 111(3):205-221. PubMed ID: 31964499
[TBL] [Abstract][Full Text] [Related]
17. Emerging systemic therapies for atopic dermatitis: biologics.
Nusbaum KB; Nguyen CM; Fleischer AB
J Dermatolog Treat; 2022 May; 33(3):1269-1273. PubMed ID: 33045848
[TBL] [Abstract][Full Text] [Related]
18. [Development of new topical substances for the treatment of atopic dermatitis].
Freimooser S; Traidl S; Werfel T
Dermatologie (Heidelb); 2022 Jul; 73(7):514-519. PubMed ID: 35608634
[TBL] [Abstract][Full Text] [Related]
19. Selective JAK1 Inhibitors for the Treatment of Atopic Dermatitis: Focus on Upadacitinib and Abrocitinib.
Ferreira S; Guttman-Yassky E; Torres T
Am J Clin Dermatol; 2020 Dec; 21(6):783-798. PubMed ID: 32776305
[TBL] [Abstract][Full Text] [Related]
20. The evolving atopic dermatitis management landscape.
Sahni VN; Balogh EA; Strowd LC; Feldman SR
Expert Opin Pharmacother; 2022 Mar; 23(4):517-526. PubMed ID: 34758685
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
